---
title: Citation Source and Traceability for Biologics Investment Research Knowledge Base Construction
slug: /en/industry/finance-d006-c105-f009
page_type: Industry scenario page
article_section: Research Knowledge Base Governance
is_part_of: FastGPT Tech Center
meta_title: Citation Source and Traceability for Biologics Investment
meta_description: Biologics data used for financial investment research decisions primarily comes from public regulatory agency announcements, clinical trial databases
source_type: Industry topic matrix (industry x direction x capability x real community questions)
date_published: 2026-09-15
date_modified: 2026-09-15
---

# Citation Source and Traceability for Biologics Investment Research Knowledge Base Construction

## What Data for This Category Looks Like
Biologics data used for financial investment research decisions primarily comes from public regulatory agency announcements, clinical trial databases, pharmaceutical company annual R&D reports, and professional academic journals. Data update cycles fluctuate with approval progress and trial timelines, with no fixed schedule. Individual documents typically include fields such as trial number, active ingredient, administration dose, indication scope, adverse event records, and approval status. Units include professional metrics like mg/mL, log10(IC50), and case counts. Document structures are mostly organized by trial phase and data type as hierarchy levels. Some long documents include multi-chapter segmented data to support investment decisions in the biopharmaceutical sector.

## Constraints These Characteristics Impose on Citation Source and Traceability
Decentralized data sources mean traceability requires linking multiple authoritative channels. Citations must include the original data publishing organization and update time to maintain credibility for financial investment research decisions. The specialized nature of fields and units requires traceability information to extract corresponding content precisely. Omitting metric identifiers can lead to errors in investment judgments. The hierarchical structure of documents requires citations to anchor to specific sections. Broad citations of entire documents can cause information deviation. Uncertain update cycles require traceability information to include version identifiers. This ensures the timeliness of cited data and meets the strict requirements of financial investment research for data accuracy.

## Configuration Settings
| Configuration Item | Recommended Value Range | Rationale |
| --- | --- | --- |
| `Recall Count` | Top 8-12 entries | Biologics investment research data is specialized and decentralized. Too many recalled entries will introduce irrelevant information, while too few will fail to cover core investment research data |
| `Similarity Threshold` | 0.75-0.85 | High proportion of specialized terminology requires a high matching threshold to filter non-relevant documents and avoid interference from low-quality content in citations |
| `Segment Length` | 800-1200 characters | Biologics documents often contain long paragraphs of trial data. Segments that are too long will disrupt professional logical connections, while segments that are too short will lose contextual information |
| `Reranked Return Count` | Top 3-5 entries | Core investment research information is concentrated in a small number of highly authoritative source documents. Prioritizing highly relevant entries simplifies traceability |
| `PARSE_FILE_TIMEOUT_SECONDS` | 600 seconds | Large clinical trial report documents take longer to parse. Extending the timeout period prevents parsing failures |
| `Traceability Version Tag Toggle` | Enabled | Biologics data updates frequently. Citations must include document versions and update times to ensure timeliness of references |

> The parameter values provided on this page are common starting points for configuration. Actual values are affected by material format, data volume, and business rules. Each scenario requires specific analysis. It is recommended to test against your own samples before finalizing settings.

## Three Common Configuration Mistakes
- Issue: No `sourceDocId` field appears in results returned when calling the chat interface. Cause: The knowledge base traceability ID return configuration is not enabled for version 3.9.2 or later, or traceability permissions for the knowledge base are not correctly bound.
- Issue: Cited content only appears at the bottom of responses, with no direct association between professional fields and units in context citations. Cause: Segment anchoring configuration is not enabled. Only overall document information is extracted, with no precise localization of professional segments.
- Issue: Conflicting active ingredient doses appear after merging knowledge base search citations. Cause: Priority rules for specialized fields are not set. This leads to incorrect merging of the same biologics data from different sources, with no retention of authoritative identifiers from the original documents.

## How to Verify Proper Configuration
- Initiate a test query containing biologics specialized terminology. Check if the returned results include document name and update time fields.
- Call the chat interface. Verify that the returned results include a citation list array containing document IDs and section information.
- Review parsed segments in the knowledge base. Confirm that each cited segment is labeled with the corresponding original document section and professional units.
- Simulate submitting queries for different versions of the same biologics data. Check if the traceability information displays the correct document update time and version identifiers.

> Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-14.
